These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 29512050)

  • 1. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.
    Derijks LJJ; Wong DR; Hommes DW; van Bodegraven AA
    Clin Pharmacokinet; 2018 Sep; 57(9):1075-1106. PubMed ID: 29512050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a personalized medicine approach to the management of inflammatory bowel disease.
    Mosli MH; Sandborn WJ; Kim RB; Khanna R; Al-Judaibi B; Feagan BG
    Am J Gastroenterol; 2014 Jul; 109(7):994-1004. PubMed ID: 24842338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical guidelines for the treatment of inflammatory bowel disease.
    Kuhbacher T; Fölsch UR
    World J Gastroenterol; 2007 Feb; 13(8):1149-55. PubMed ID: 17451192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine.
    Lefevre PLC; Shackelton LM; Vande Casteele N
    BioDrugs; 2019 Oct; 33(5):453-468. PubMed ID: 31301024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are patients with IBD knowledgeable about the risks of their medications?
    Keohane J; Shanahan F
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S70-1. PubMed ID: 18816750
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical management of the pregnant patient with inflammatory bowel disease.
    Steinlauf AF; Present DH
    Gastroenterol Clin North Am; 2004 Jun; 33(2):361-85, xi. PubMed ID: 15177544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF Antibodies and Autophagy: A Hidden Nexus for a Successful Therapeutic Response?
    Genua M; Becker C; Vetrano S
    J Crohns Colitis; 2016 Mar; 10(3):237-8. PubMed ID: 26645640
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.
    Quetglas EG; Mujagic Z; Wigge S; Keszthelyi D; Wachten S; Masclee A; Reinisch W
    World J Gastroenterol; 2015 Nov; 21(44):12519-43. PubMed ID: 26640330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.
    El Mourabet M; El-Hachem S; Harrison JR; Binion DG
    Curr Drug Targets; 2010 Feb; 11(2):234-41. PubMed ID: 19916950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events of IBD therapies.
    Scribano ML
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S210-1. PubMed ID: 18816669
    [No Abstract]   [Full Text] [Related]  

  • 13. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.
    Wilson DC; Thomas AG; Croft NM; Newby E; Akobeng AK; Sawczenko A; Fell JM; Murphy MS; Beattie RM; Sandhu BK; Mitton SG; ; Casson D; Elawad M; Heuschkel R; Jenkins H; Johnson T; Macdonald S; Murch SH
    J Pediatr Gastroenterol Nutr; 2010 Feb; 50 Suppl 1():S14-34. PubMed ID: 20081542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy and inflammatory bowel disease: a prospective case-control study.
    Malgarinos G; Gikas A; Delicha E; Stamataki A; Georgopoulos F; Papadimitriou A; Stanciu C; Triantafillidis JK
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(3):613-9. PubMed ID: 18293689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics in IBD: ready for prime time?
    Roblin X; Rinaudo M; Sparrow MP; Moreau A; Phelip JM; Genin C; Lamarque D; Paul S
    Curr Drug Targets; 2014; 15(11):1049-55. PubMed ID: 25173707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse events associated with the treatment of inflammatory bowel disease].
    Meyer L; Simian D; Lubascher J; Acuña R; Figueroa C; Silva G; Brahm J; Quera R
    Rev Med Chil; 2015 Jan; 143(1):7-13. PubMed ID: 25860263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and management of inflammatory bowel disease in the older patient.
    Ha CY; Katz S
    Curr Gastroenterol Rep; 2013 Feb; 15(2):310. PubMed ID: 23307425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of inflammatory bowel disease.
    Katsanos KH; Papadakis KA
    Pharmacogenomics; 2014 Dec; 15(16):2049-62. PubMed ID: 25521361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.